Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

NCT05164341 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Partial Lipodystrophy

Interventions

DRUG: metreleptin
DRUG: Placebo

Sponsor

Amryt Pharma